Methadone
Viewing r1 — Apr 27, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Methadone is a synthetic opioid of the diphenylheptanone class. It targets the same receptors as morphine and heroin through a structurally unrelated open-chain design. Beyond opioid activation, it also blocks glutamate signaling[1] — a combination rare among opioids that shapes both its clinical effectiveness and its risk profile.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, heroin, oxycodone +6 moremorphine, heroin, oxycodone, hydrocodone, fentanyl, codeine, buprenorphine, tramadol, hydromorphone show less
Methadone was synthesized in Germany in 1937–1938 as an alternative to morphine.[2] In 1965, Dole and Nyswander demonstrated that daily oral methadone suppressed heroin craving and blocked its reinforcement, launching methadone maintenance treatment.[3] The WHO recognizes it as an essential medicine,[4] but it remains among the most heavily regulated and stigmatized medications in clinical use.
Subjective effects include pain suppression, sedation, emotional quieting, and mild euphoria. Effects build over hours rather than arriving as a rush — a sustained warmth and bodily heaviness that feels more like stabilization than intoxication. Nausea, constipation, and cognitive slowing are characteristic unwanted effects; high doses or first exposure produce pronounced sedation.
Methadone produces rapid physical dependence, and the gap between a therapeutic dose and a fatal one is narrow.[5] Its slow elimination creates an accumulation hazard, and it directly disrupts the heart's electrical rhythm — a toxicity unusual among opioids.[6] Seven decades of clinical data make it one of the most studied opioids, though wide individual variability in metabolism means dosing remains imperfect.[7]
History[edit]
Discovery
Methadone was synthesized in Germany in 1937–1938 by Max Bockmühl and Gustav Ehrhart, developed as a structurally novel alternative to morphine at a time when Germany sought to reduce dependence on imported opium.[2][8] It reached American clinical use in 1947 under the trade name Dolophine.[9]
Clinical significance
In 1965, Vincent Dole and Marie Nyswander demonstrated that daily oral methadone suppressed heroin craving and blocked its reinforcement, establishing methadone maintenance treatment.[3] The WHO added methadone to its Model List of Essential Medicines in 2005, recognizing its role in treating opioid use disorder and reducing HIV transmission among people who inject drugs.[4]
Regulation
In the United States, methadone faces a uniquely restrictive three-tier regulatory framework when used for addiction treatment — FDA manufacturing standards, DEA Schedule II controls, and SAMHSA certification — a structure applied to no other medication.[9] This structure has been criticized for limiting access to life-saving treatment.
The name Dolophine comes from the Latin dolor (pain) and French fin (end) — not from "Adolf," as a persistent myth claims.[2] Methadone's cultural identity is inseparable from addiction treatment: simultaneously one of the most effective and most stigmatized medications in modern medicine.
Chemistry[edit]
Structural class
Methadone belongs to the diphenylheptanone class of synthetic opioids — an open-chain architecture structurally unrelated to morphine and most other clinical opioids.[2] Its molecular formula is C₂₁H₂₇NO (molecular weight 309.4 g/mol). It is dispensed clinically as the hydrochloride salt (methadone HCl).[10]
Pharmacology[edit]
Mechanism of action
Methadone is a full opioid agonist — it activates opioid receptors completely, producing pain suppression, sedation, and respiratory depression.[7] It also blocks glutamate signaling at clinically relevant doses,[1][11] which may improve effectiveness against nerve pain and slow the development of tolerance.[12]
It also blocks cardiac electrical channels[6] and slows the removal of serotonin from synapses[13][14] — two properties that create serious toxicity risks not seen with most opioids.
Pharmacokinetics
Taken orally, methadone absorbs well and peaks 2.5 to 4 hours after a dose, but its defining feature is a half-life ranging from 5 to 130 hours across individuals — producing up to 17-fold differences in blood concentration at the same dose.[7] The liver enzyme CYP2B6 drives most of its metabolism, and genetic variation here alters both opioid and cardiac risk.[15][16][17]
Neuroscience[edit]
Where it acts
Methadone activates opioid receptors in a deep brain region that releases dopamine — producing the reinforcement and mild euphoria associated with opioids.[18] In maintenance treatment, steady blood levels replace the surge-and-crash pattern of short-acting opioids with a stable, continuous signal.
Pain relief works through a separate pathway: opioid receptors in the brainstem and spinal cord block incoming pain signals.[19] Blocking glutamate signaling at spinal sites may also counter the amplification of chronic pain.[1][12]
Why it matters
Methadone maintenance works by stabilizing two systems that opioid dependence disrupts. Steady dosing reduces craving and drug-cue reactivity while flattening the reinforcing highs that make heroin hard to stop.[18] It also interrupts the cycle of between-dose withdrawal that progressively worsens the brain's baseline state.[18]
Whether methadone's preference for one receptor signaling pathway[20] translates to meaningful differences in tolerance or overdose risk compared to other opioids remains unknown. The contribution of glutamate blockade to pain relief in humans has not been separated from the dominant opioid effect.[21][19] Whether genetic testing for metabolizer status could reduce methadone deaths remains untested in prospective trials.[22][23][17]
Subjective Effects[edit]
Methadone's defining quality is gradualism. Effects build over hours rather than arriving in a rush — producing sustained warmth, emotional quieting, and bodily heaviness that feel more like stabilization than intoxication. At therapeutic doses in maintenance patients, the experience often registers as normalized function rather than overt psychoactivity.
Compared to heroin or oxycodone, methadone delivers less acute euphoric intensity but far greater duration — a trade-off that defines both its therapeutic value and its accumulation risk. Relative to buprenorphine, it activates opioid receptors more completely, providing deeper analgesia and sedation at high doses but greater respiratory depression risk.
Effect Grid
At common doses, the full opioid effect profile manifests: pronounced analgesia, significant sedation, and cognitive euphoria — a warm, contented mental state with reduced emotional reactivity. Anxiety suppression is strong. Pain awareness diminishes substantially. The experience lacks the intense rush of IV heroin but produces sustained well-being over many hours.
Physically, pupil constriction is marked. Nausea occurs frequently in those without tolerance. Constipation is reliable. Respiratory rate decreases measurably. Itching and sweating are common. Urinary retention may occur.
The extended duration (10–19 hours of total effects) and long half-life mean residual sedation persists well beyond the peak. Sleep is easily induced. Cognitive and psychomotor impairment is significant.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Internal hallucinations
Sedation · Nausea · Bodily heaviness · Body high · Breathing alteration · Excessive sweating · Muscle relaxation · Tactile euphoria · Spontaneous body sensations · Sexual arousal suppression · Appetite suppression · Dizziness · Physical fatigue · Dry mouth · Temperature dysregulation · Vomiting · Abnormal heartbeat · Headache · Tingling / electric sensations · Heart rate perception changes · Nystagmus (eye wobbles) · Pain enhancement · Bodily dissociation
Body high · Breathing alteration · Excessive sweating · Muscle relaxation · Tactile euphoria · Spontaneous body sensations · Sexual arousal suppression · Appetite suppression · Dizziness · Physical fatigue · Dry mouth · Vomiting · Abnormal heartbeat · Headache · Tingling / electric sensations · Heart rate perception changes · Nystagmus (eye wobbles) · Pain enhancement · Bodily dissociation
Focus suppression · Information processing suppression · Thought deceleration · Cognitive euphoria · Motivation suppression · Confusion · Language suppression · Memory suppression · Cognitive dysphoria · Memory fragmentation · Thought disorganization · Amnesia · Delirium
Cognitive euphoria · Motivation suppression · Confusion · Language suppression · Memory suppression · Cognitive dysphoria · Memory fragmentation · Thought disorganization · Delirium
Irritability · Dysphoria
Sociability suppression · Social disconnection · Depersonalization · Derealization · Cognitive disconnection
Cognitive disconnection
Timeline
First subtle awareness emerges 20–90 minutes after ingestion: faint warmth, slight mood shift, initial hint of pain relief. Effects are easily overlooked at lower doses.
Gradual intensification over 1. 5–4 hours as plasma levels approach Tmax. Sedation, analgesia, and anxiolysis build steadily.
Maximum subjective intensity at 4–6 hours: full analgesia, deepest sedation, strongest euphoria and anxiolysis. Respiratory depression is at its greatest. Pupil constriction is maximal.
Sustained but gradually diminishing opioid effects over 3–5 hours. Sedation and analgesia remain significant. The long half-life maintains plasma levels well above the minimum effective concentration.
Slow decline over 4–6 hours. Residual sedation and mild analgesia persist. Mood returns toward baseline.
Residual effects lasting 1–24 hours after primary effects resolve: mild drowsiness, constipation, subtle mood effects. Psychomotor impairment and cognitive slowing may persist beyond subjective awareness.
⚠ Do not drive or operate heavy machinery for at least 24 hours after ingestion, as residual sedation and slowed reaction time persist well beyond the perceived end of effects.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- morphine · heroin · oxycodone
Toxicity
QT prolongation and cardiac risk
Methadone disrupts the heart's electrical rhythm — a condition called QT interval prolongation — which can trigger a potentially fatal irregular heartbeat called torsades de pointes.[6][24] The American Heart Association specifically names methadone among drugs capable of this effect.[25]
Risk is highest at doses above 100 mg/day, when combined with other QT-prolonging drugs, or in people with low potassium levels, pre-existing heart conditions, or certain genetic variants that raise the more cardiotoxic form of methadone in the blood.[26][25][17]
Respiratory depression and overdose
Stopped or severely slowed breathing is the primary mechanism of fatal methadone overdose.[27] The first weeks of treatment carry the highest mortality risk.[23][28]
Methadone's long duration creates an accumulation hazard: pain suppression fades before respiratory depression fully clears, and redosing into that gap is a common path to fatal overdose. Fatal blood concentrations overlap substantially with therapeutic levels in tolerant patients,[5] and the vast majority of methadone fatalities involve other substances — especially benzodiazepines and antidepressants.[29]
Genetic risk factors
A genetic variant affecting the liver enzyme CYP2B6 can significantly raise methadone blood levels, independently increasing the risk of fatal outcomes.[23][17] This enzyme preferentially clears the more cardiotoxic form of methadone, so reduced function compounds both respiratory and cardiac risk.
Therapeutic index
Methadone has a narrow therapeutic index — the overlap between therapeutic and fatal blood concentrations[5] leaves little margin for error, particularly in opioid-naive individuals and those with the CYP2B6 poor metabolizer variant. The margin narrows further with concurrent depressant use.
Psychological risks
Methadone does not cause hallucinations or psychosis. The main psychological risks are:
- Dependence and compulsive use: psychological dependence develops alongside physical dependence.[18]
- Cognitive impairment: sedation and thought deceleration, especially during early treatment and dose increases.
- Withdrawal mood disturbance: anxiety, irritability, low mood, and insomnia during dose reduction or discontinuation.
- Psychosocial burden: Stigma, perceived loss of autonomy, and ambivalence about indefinite treatment are commonly reported.
Tolerance & dependence
Tolerance develops as opioid receptors become less responsive,[30] and it builds faster to sedation and euphoria than to pain relief — which can drive dose escalation. Physical dependence is high. Withdrawal begins 36–72 hours after the last dose — later than short-acting opioids — and can persist for weeks, with symptoms including muscle aches, diarrhea, insomnia, and anxiety.[31]
Methadone maintenance deliberately uses this dependence therapeutically. A Cochrane meta-analysis confirms it retains patients and suppresses heroin use more effectively than non-opioid treatments,[32] and all-cause mortality is threefold lower during treatment than off it.[28]
Drug interactions
Respiratory depression synergy
benzodiazepines and alcohol amplify methadone's suppression of breathing through different mechanisms.[33][34] Benzodiazepines are the most commonly co-detected substance in methadone fatalities.[27] Combining methadone with GHB or Alcohol carries lethal risk through additive suppression of breathing and consciousness. Combined use with ketamine poses theoretical risk through overlapping sedation.safety citation needed
Serotonin syndrome
Combining methadone with MAOIs, SSRIs, SNRIs, or tricyclic antidepressants can trigger serotonin syndrome — a potentially life-threatening state of overheating, rapid heart rate, muscle rigidity, and seizures — because methadone slows serotonin removal from synapses.[13][14][35] MAOIs carry the highest risk and are potentially lethal in combination.
Tramadol is especially dangerous — it both slows serotonin clearance and activates opioid receptors, producing serotonin syndrome and enhanced respiratory depression simultaneously.[13][35]
Drugs that alter methadone levels
Some drugs speed up liver breakdown of methadone (rifampicin, phenytoin, carbamazepine, efavirenz, nevirapine), dropping blood levels sharply and potentially triggering withdrawal in maintained patients. Others slow it (fluconazole, paroxetine, grapefruit juice[36]), raising levels and increasing both opioid and cardiac risk.[7][15]
QT-prolonging drug combinations
Combining methadone with other drugs that disrupt heart rhythm — antipsychotics, azithromycin, antiarrhythmics — synergistically raises the risk of a potentially fatal irregular heartbeat.[25]
Contraindications
Absolute contraindications
- Concurrent MAOI use: High risk of lethal serotonin syndrome.[13][35]
- Severe respiratory insufficiency: Methadone's respiratory depressant effects may be fatal in those with pre-existing breathing compromise.
Relative contraindications
- QT-prolonging conditions or medications: Significant cardiac risk; ECG monitoring required at initiation and dose changes.[26][25]
- CYP2B6 poor metabolizer phenotype (especially *6/*6 genotype): Elevated blood levels; dose reduction and enhanced monitoring required.[17][23]
- Liver impairment: Impaired metabolism increases accumulation risk.
- Concurrent benzodiazepine use: Additive respiratory depression; if unavoidable, dose reduction and respiratory monitoring are essential.[27]
- Pregnancy: Methadone maintenance is the standard of care for pregnant women with opioid use disorder, but it crosses the placenta and causes neonatal withdrawal syndrome. Monitoring to day of life 5 is recommended.citation needed
Harm Reduction[edit]
Forms & Identification
In clinical settings, methadone comes in tightly controlled pharmaceutical forms — tablets, liquid concentrate, and dispersible wafers — with consistent dosing. Outside clinical dispensing, confirming identity and dose strength is the main challenge when tablets are obtained without labeling. Fentanyl test strips should be used on any opioid from unregulated sources, as fentanyl contamination is the leading cause of unexpected opioid overdose.
Guidelines
- Test before use. Confirm identity and dose when obtaining methadone outside a clinical program. Use fentanyl test strips on any opioid from unregulated sources.
- Start low, wait long. Peak effect takes hours, not minutes. Do not redose within 4 hours of an oral dose — accumulation kills more people than initial overdose.
- Keep naloxone accessible. Anyone using methadone — prescribed or not — should have naloxone within reach. Multiple doses may be needed given methadone's long duration.
- Avoid mixing with depressants. Alcohol and benzodiazepines are the most common co-factors in methadone deaths. Even prescribed benzodiazepines substantially increase risk.
- Have a sitter during induction. The first days of methadone use carry the highest mortality risk. Another person who knows the signs of overdose can save a life.
- Stay hydrated and nourished. Methadone causes constipation and can suppress appetite. Maintain fluid and fiber intake proactively.
Set & Setting
Methadone's slow onset and long duration reward patience and punish impulsivity. The 2.5–4 hour time to peak effect means redosing before the full effect arrives is one of the most dangerous patterns with this substance. A calm, familiar environment reduces the sedation amplified by anxiety and disorientation, especially during the first days of use or dose adjustment.
Aftercare & integration. For people in maintenance treatment, aftercare is ongoing rather than a post-experience recovery. Regular medical monitoring — including periodic ECG assessment for QT prolongation — is standard. Managing side effects such as constipation, sweating, and reduced sex drive improves quality of life and treatment retention.
For those considering tapering or discontinuation, gradual dose reduction over months minimizes discomfort and relapse risk. Professional guidance during tapering is strongly recommended. Post-discontinuation, sleep disruption and low mood may persist for weeks to months.
Recovery & Support
Methadone maintenance itself is a recovery intervention — a Cochrane meta-analysis confirms it retains patients and suppresses heroin use more effectively than non-opioid treatments,[32] and all-cause mortality is threefold lower during treatment than off it.[28] Ambivalence about ongoing treatment is common and does not indicate failure.
For those seeking to end methadone use, medically supervised tapering combined with psychosocial support offers the best outcomes. Mutual aid groups (NA, SMART Recovery) and peer support services can supplement clinical care. The transition from methadone to abstinence or buprenorphine should be medically guided — abrupt discontinuation carries high relapse risk and significant physical distress.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow, shallow, or stopped breathing; blue or gray lips and fingertips; snoring or gurgling sounds in an unresponsive person; pinpoint pupils with loss of consciousness. Methadone overdose can develop gradually — a person who seems "just sleepy" may deteriorate over hours due to accumulation.
Immediate steps:
- Call emergency services immediately.
- Administer naloxone (intranasal or intramuscular) if available. Methadone's long duration means naloxone may wear off before the methadone does — be prepared to give additional doses and monitor continuously.
- Place the person in the recovery position (on their side) if breathing but unresponsive.
- Stay with the person until help arrives.
- Do NOT induce vomiting. Do NOT leave the person alone.
What to tell the dispatcher: Name the substance (methadone), estimated amount and time taken, symptoms observed, and whether naloxone has been given. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Reversal agent: Naloxone reverses opioid respiratory depression. Because methadone outlasts naloxone, repeated doses or continuous monitoring after administration are essential — relapse into respiratory depression is expected.
Legal Status[edit]
International framework
Methadone is controlled internationally under the UN Single Convention on Narcotic Drugs (1961) while simultaneously recognized as a WHO essential medicine[4] — a dual status reflecting its medical value alongside high abuse liability.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | DEA Schedule II; for addiction treatment, dispensing restricted to licensed Opioid Treatment Programs (OTPs); three-tier regulation: FDA + DEA + SAMHSA[9] |
| United Kingdom | Class A, Schedule 2 (Misuse of Drugs Act 1971) | Illegal without prescription; maximum penalties for unauthorized possession and supply |
| Canada | Schedule I (Controlled Drugs and Substances Act) | As of 2018, no Health Canada exemption required to prescribe; accessible through standard prescribing authority |
| Germany | Anlage III (Betäubungsmittelgesetz) | Prescribable on special narcotic prescription form; levomethadone (Polamidon) available as pure R-enantiomer |
| Australia | Schedule 8 (Controlled Drug) | Drug of dependence under state/territory controlled substances regulationscitation needed |
| International | Schedule I (UN Single Convention on Narcotic Drugs, 1961) | WHO Essential Medicine (14th Model List, 2005)[4] |
Regulatory distinctiveness
In the United States, methadone is the only medication subject to a three-tier federal framework (FDA + DEA + SAMHSA) when used for addiction treatment.[9] When prescribed for pain, standard Schedule II rules apply without the treatment program requirement — a bifurcated structure criticized for limiting treatment access.
Legal status varies by jurisdiction and changes frequently. This information is for educational purposes only and does not constitute legal advice.
references
- [1] ^abcEbert B, Andersen S, Krogsgaard-Larsen P (1995) Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. — Neuroscience Letters PMID:7624018
- [2]
- [3] ^abDole VP, Nyswander M (1965) A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE. — JAMA PMID:14321530
- [4] ^abcdHerget G (2005) Methadone and buprenorphine added to the WHO list of essential medicines. — HIV/AIDS Policy & Law Review PMID:16544403
- [5] ^abcPelletti G, Giunchi V, Fais P, et al. (2026) Characterizing post-mortem blood concentrations in methadone-related deaths. — International Journal of Legal Medicine doi:10.1007/s00414-025-03620-0
- [6] ^abcZünkler BJ, Wos-Maganga M (2010) Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels. — Cardiovascular Toxicology doi:10.1007/s12012-010-9074-y